Eisai Co., Ltd

(PINK:ESALF)

Latest On Eisai Co., Ltd (ESALF):

Date/Time Type Description Signal Details
2023-05-15 17:45 ESTNewsEisai GAAP EPS of ¥193.31, revenue of ¥744.4BN/A
2023-05-15 17:45 ESTNewsEisai Co., Ltd. (ESALF) Q4 2022 Earnings Call TranscriptN/A
2023-05-14 12:27 ESTNewsBiogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – studyN/A
2023-04-27 00:22 ESTNewsBiogen gains as Medicare to cover new Alzheimer’s drug with full FDA approvalN/A
2023-04-21 15:08 ESTNewsEli Lilly expects Medicare coverage for Alzheimer's drugs - ReutersN/A
2023-04-20 16:06 ESTNewsEisai: Potentially The Best Bet On The Alzheimer's Treatment MarketN/A
2023-04-17 15:31 ESTNewsBiogen's Leqembi has questionable efficacy, cost effectiveness, ICER saysN/A
2023-04-10 15:28 ESTNewsBiogen, Eisai to face FDA AdCom in June for full approval of Alzheimer's drugN/A
2023-04-07 12:48 ESTNewsMerck, Eisai end two Keytruda combination trials after missing main goalsN/A
2023-03-20 22:14 ESTNewsBiogen, Eisai Alzheimer's drug Leqembi covered by VAN/A
2023-03-10 16:44 ESTNewsEisai expects $7B sales from Biogen-partnered Alzheimer’s therapy in 2030N/A
2023-03-01 19:29 ESTNewsBiogen, Eisai's Alzheimer's therapy lecanemab gets priority review in ChinaN/A
2023-02-28 12:58 ESTNewsBiogen, Eisai's Alzheimer's therapy lecanemab gets priority review in ChinnaN/A
2023-02-26 04:27 ESTNewsEisai: Growth In Japan Markets, Leqembi The Main Long-Term Growth DriverN/A
2023-02-23 08:51 ESTNewsMedicare says coverage limits on Alzheimer’s drugs is not under reviewN/A
2023-02-17 23:58 ESTNewsEisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBCN/A
2023-02-17 23:58 ESTNewsSenators urge swift action to expand Medicare coverage for Alzheimer’s therapiesN/A
2023-02-06 11:50 ESTNewsEisai Co., Ltd. 2022 Q3 - Results - Earnings Call PresentationN/A
2023-02-06 11:49 ESTNewsEisai Co., Ltd. (ESALF) Q3 2022 Earnings Call TranscriptN/A
2023-01-30 08:23 ESTNewsBiogen, Eisai's Alzheimer's drug lecanemab gets priority review in JapanN/A
2023-01-27 15:55 ESTNewsBiogen, Eisai's Alzheimer's drug lecanemab gets review in EUN/A
2023-01-16 04:13 ESTNewsEisai files application in Japan for Alzheimer's drug lecanemabN/A
2023-01-11 04:52 ESTNewsEisai files for approval of Alzheimer's drug lecanemab in EUN/A
2023-01-07 21:12 ESTNewsBiogen, Eisai's lecanemab gets Alzheimer's nod, but how successful it will be is uncertainN/A
2023-01-06 19:18 ESTNewsBiogen, Eisai's Alzheimer's treatment lecanemab approved by the FDAN/A
2022-12-30 02:06 ESTNewsBiogen, FDA faulted in congressional inquiry into Alzheimer’s drug approvalN/A
2022-12-23 17:17 ESTNewsEisai starts filing seeking approval for Alzheimer's drug lecanemab in ChinaN/A
2022-12-23 17:17 ESTNewsBiogen/ Eisai deserve $30K price tag for new Alzheimer’s drug – Wells FargoN/A
2022-12-23 17:17 ESTNewsBiogen, Eisai Alzheimer's candidate lecanemab linked to third patient deathN/A
2022-12-23 00:43 ESTNewsBiogen, Lilly potential Alzheimer's drugs given lukewarm review by drug evaluation groupN/A
2022-12-22 06:48 ESTNewsAstellas Pharma, Eisai, Daiichi Sankyo and Takeda join hands to reduce environmental burden in the field of pharmaceutical packagingN/A
2022-12-08 17:45 ESTNewsBiogen, Eisai prompt Medicare to reevaluate Alzheimer’s coverage after new dataN/A
2022-12-01 21:30 ESTNewsLecanemab And Alzheimer's: More DataN/A
2022-12-01 21:30 ESTNewsLilly posts Phase 3 data to compare its Alzheimer’s drug vs. Biogen’sN/A
2022-12-01 03:15 ESTNewsBiogen rallies Alzheimer’s drug developers after full data for lecanemabN/A
2022-11-30 09:40 ESTNewsBiogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swellingN/A
2022-11-30 09:39 ESTNewsBiogen stock may see pressure after not mentioned in Alzheimer's presentation - analystN/A
2022-11-28 21:53 ESTNewsBiogen drops after report on second death linked to Alzheimer’s candidateN/A
2022-11-08 04:06 ESTNewsEisai Co., Ltd. (ESALF) Q2 2023 Earnings Call TranscriptN/A
2022-10-28 08:53 ESTNewsBiogen slips amid reports of death linked to new Alzheimer’s drugN/A
2022-10-01 02:41 ESTNewsEisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The RescueN/A
2022-08-23 20:43 ESTNewsEisai, C2N team up to build real-world evidence for blood-based tests for cognitive disordersN/A
2022-08-06 18:11 ESTNewsEisai Co., Ltd. 2023 Q1 - Results - Earnings Call PresentationN/A
2022-08-06 18:11 ESTNewsEisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call TranscriptN/A
2022-07-20 01:05 ESTNewsEisai refocuses R&D efforts as cancer research unit shuttersN/A
2022-07-06 14:42 ESTNewsBiogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority reviewN/A
2022-06-24 17:44 ESTNewsBiogen pulls plug on Aduhelm real-world study on coverage woesN/A
2022-05-14 06:50 ESTNewsEisai Co., Ltd. (ESALF) CEO Haruo Naito on Q4 2022 Results - Earnings Call TranscriptN/A
2022-05-10 18:31 ESTNewsBiogen, Eisai finish filing with FDA for Alzheimer’s therapy lecanemab, seek priority reviewN/A
2022-04-10 06:44 ESTNewsHow might the CMS decision on Biogen's Aduhelm impact other Alzheimer's candidates?N/A

About Eisai Co., Ltd (ESALF):

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

ESALF Quotes by TradingView

See Advanced Chart

General

  • Name Eisai Co., Ltd
  • Symbol ESALF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 10,998
  • Fiscal Year EndMarch
  • Web URLhttp://www.eisai.co.jp
View More

Valuation

  • Trailing PE 34.36
  • Forward PE 27.7
  • Price/Sales (Trailing 12 Mt.) 3.16
  • Price/Book (Most Recent Quarter) 3.33
  • Enterprise Value Revenue 0.03
  • Enterprise Value EBITDA 0.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $1.77
  • Next Year EPS Estimate $2.57
  • Profit Margin 13%
  • Return on Assets 6%
  • Return on Equity 14%
  • Earnings Per Share $2.08
  • Revenue Per Share $0
  • Gross Profit 519.93 billion
  • Quarterly Earnings Growth -3%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 32.02
  • Environment Score 1.86
  • Social Score 14.39
  • Governance Score 11.77
  • Controversy Level 1
View More

Highlights

  • Market Capitalization 20.03 billion
  • PEG Ratio 244930
  • Analyst Target Price $91.82
  • Book Value Per Share $19.95
View More

Share Statistics

  • Shares Outstanding 286.58 million
  • Shares Float 285.78 million
  • % Held by Insiders 917%
  • % Held by Institutions 37.94%
View More

Technicals

  • Beta 0.48
  • 52 Week High $90.35
  • 52 Week Low $22
  • 50 Day Moving Average 72.3
  • 200 Day Moving Average 76.63
View More

Dividends

  • Forward Annual Dividend Rate $1.49
  • Forward Annual Dividend Yield 2.09%
  • Payout Ratio 105%
  • Dividend Date 2018-05-24
  • ExDividend Date 2021-03-30
  • Dividend Per Share $1.36
  • Dividend Yield 0%
View More

Eisai Co., Ltd (ESALF) Dividend Calendar:

ESALF's last dividend payment was made to shareholders on May 24, 2018.
Eisai Co., Ltd pays out 105% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount
2023-09-292023-11-172023-09-302023-05-15$80
2023-03-302023-05-292023-03-312022-05-13$80
2022-09-292022-11-182022-09-302022-05-13$80
2022-03-302022-05-252022-03-312021-05-12$80
2021-09-292021-11-192021-09-302021-05-12$80
2021-03-302021-05-212021-03-312020-05-13$80
2020-09-292020-11-192020-09-302020-05-13$80
2020-03-302020-05-222020-03-312019-05-13$80
2019-09-272019-11-192019-09-302019-05-13$80
2019-03-292019-05-222019-03-312018-05-15$80
2018-09-282018-11-192018-09-302018-05-15$70
2018-03-292018-05-242018-03-312017-05-10$80
2017-03-302017-05-192017-03-312016-05-13$80
2016-09-292016-11-182016-09-302016-05-13$70
2016-03-302016-05-232016-03-312015-05-14$80
2021-03-300000-00-002021-03-312020-05-13$80
2020-03-302020-03-312019-05-13$80

Eisai Co., Ltd (ESALF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.65
2020-09-302020-12-31$N/A$0.65
2020-06-302020-09-30$N/A$0.05$42.20-99.89%
2020-03-312020-06-30$N/A$0.79
2019-12-312020-03-31$1.72 billion$1.57
2019-09-302019-12-31$1.34 billion$1.49$63.85-97.67%
2019-06-302019-09-30$1.42 billion$0.17
2019-03-312019-06-30$1.58 billion$0.70
2018-12-312019-03-31$1.43 billion$0.74
2018-09-302018-12-31$1.38 billion$0.23
2018-06-302018-09-30$1.38 billion$0.62$36.30-98.28%
2018-03-312018-06-30$1.51 billion$0.39$96.80-99.6%
2017-12-312018-03-31$1.37 billion$0.78$36.70-97.88%
2017-09-302017-12-31$1.27 billion$0.29$24.20-98.81%
2017-06-302017-09-30$1.26 billion$0.28$24.90-98.88%
2017-03-312017-06-30$129.87 billion$0.30
2016-12-312017-03-31$0.03$30.50-99.9%
2016-09-302016-12-31$0.31$12.90-97.57%
2016-06-302016-09-30$0.28$32.65-99.14%
2016-03-312016-06-30$0.67$8.40-92.01%
2015-12-312016-03-31$0.52$21.80-97.63%
2015-09-302015-12-31$0.79
2015-06-302015-09-30$0.16$9.50-98.29%
2015-03-312015-06-30$0.16
2014-12-312015-03-31$0.19$24.00-99.21%
2014-09-302014-12-31$0.77$28.50-97.31%
2014-06-302014-09-30$0.15$20.30-99.26%
2014-03-312014-06-30$0.20$54.70-99.64%
2013-12-312014-03-31$0.12$50.30-99.77%
2013-09-302013-12-31$0.06
2013-06-302013-09-30$0.65
2013-03-312013-06-30$0.33
2012-12-312013-03-31$0.53
2012-09-302012-12-31$0.39
2012-06-302012-09-30$0.57
2012-03-312012-06-30$0.52
2011-12-312012-03-31$0.40
2011-09-302011-12-31$0.72
2011-06-302011-09-30$0.90
2011-03-312011-06-30$0.59
2010-12-312011-03-31$0.00
2010-09-302010-12-31$1.19
2010-06-302010-06-30$0.72

Eisai Co., Ltd (ESALF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Eisai Co., Ltd (ESALF) Chart:

Eisai Co., Ltd (ESALF) News:

Below you will find a list of latest news for Eisai Co., Ltd (ESALF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eisai Co., Ltd (ESALF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Eisai Co., Ltd (ESALF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link